174 related articles for article (PubMed ID: 25355639)
41. Two proliferation-related proteins, TYMS and PGK1, could be new cytotoxic T lymphocyte-directed tumor-associated antigens of HLA-A2+ colon cancer.
Shichijo S; Azuma K; Komatsu N; Ito M; Maeda Y; Ishihara Y; Itoh K
Clin Cancer Res; 2004 Sep; 10(17):5828-36. PubMed ID: 15355913
[TBL] [Abstract][Full Text] [Related]
42. Inhibition of serine-peptidase activity enhances the generation of a survivin-derived HLA-A2-presented CTL epitope in colon-carcinoma cells.
Preta G; Marescotti D; Fortini C; Carcoforo P; Castelli C; Masucci M; Gavioli R
Scand J Immunol; 2008 Dec; 68(6):579-88. PubMed ID: 19000094
[TBL] [Abstract][Full Text] [Related]
43. A cyclophilin B gene encodes antigenic epitopes recognized by HLA-A24-restricted and tumor-specific CTLs.
Gomi S; Nakao M; Niiya F; Imamura Y; Kawano K; Nishizaka S; Hayashi A; Sobao Y; Oizumi K; Itoh K
J Immunol; 1999 Nov; 163(9):4994-5004. PubMed ID: 10528204
[TBL] [Abstract][Full Text] [Related]
44. Recognition of six-transmembrane epithelial antigen of the prostate-expressing tumor cells by peptide antigen-induced cytotoxic T lymphocytes.
Rodeberg DA; Nuss RA; Elsawa SF; Celis E
Clin Cancer Res; 2005 Jun; 11(12):4545-52. PubMed ID: 15958640
[TBL] [Abstract][Full Text] [Related]
45. Definition of an immunogenic region within the ovarian tumor antigen stratum corneum chymotryptic enzyme.
Bondurant KL; Crew MD; Santin AD; O'Brien TJ; Cannon MJ
Clin Cancer Res; 2005 May; 11(9):3446-54. PubMed ID: 15867247
[TBL] [Abstract][Full Text] [Related]
46. MHC class I-presented lung cancer-associated tumor antigens identified by immunoproteomics analysis are targets for cancer-specific T cell response.
Shetty V; Sinnathamby G; Nickens Z; Shah P; Hafner J; Mariello L; Kamal S; Vlahović G; Lyerly HK; Morse MA; Philip R
J Proteomics; 2011 May; 74(5):728-43. PubMed ID: 21362506
[TBL] [Abstract][Full Text] [Related]
47. Melanocortin 1 Receptor-derived peptides are efficiently recognized by cytotoxic T lymphocytes from melanoma patients.
González FE; Ramírez M; Allerbring EB; Fasching N; Lundqvist A; Poschke I; Achour A; Salazar-Onfray F
Immunobiology; 2014 Mar; 219(3):189-97. PubMed ID: 24192537
[TBL] [Abstract][Full Text] [Related]
48. Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen.
Zaremba S; Barzaga E; Zhu M; Soares N; Tsang KY; Schlom J
Cancer Res; 1997 Oct; 57(20):4570-7. PubMed ID: 9377571
[TBL] [Abstract][Full Text] [Related]
49. Identification of novel CD33 antigen-specific peptides for the generation of cytotoxic T lymphocytes against acute myeloid leukemia.
Bae J; Martinson JA; Klingemann HG
Cell Immunol; 2004 Jan; 227(1):38-50. PubMed ID: 15051513
[TBL] [Abstract][Full Text] [Related]
50. The TAG family of cancer/testis antigens is widely expressed in a variety of malignancies and gives rise to HLA-A2-restricted epitopes.
Adair SJ; Carr TM; Fink MJ; Slingluff CL; Hogan KT
J Immunother; 2008 Jan; 31(1):7-17. PubMed ID: 18157007
[TBL] [Abstract][Full Text] [Related]
51. HLA-A2.1/K(b) transgenic murine dendritic cells transduced with an adenovirus encoding human gp100 process the same A2.1-restricted peptide epitopes as human antigen-presenting cells and elicit A2.1-restricted peptide-specific CTL.
Yang S; Linette GP; Longerich S; Roberts BL; Haluska FG
Cell Immunol; 2000 Aug; 204(1):29-37. PubMed ID: 11006015
[TBL] [Abstract][Full Text] [Related]
52. Generation of cytotoxic T lymphocytes specific for native or modified peptides derived from the epidermal growth factor receptor pathway substrate 8 antigen.
Li Y; Zhou W; Du J; Jiang C; Xie X; Xue T; He Y
Cancer Immunol Immunother; 2015 Feb; 64(2):259-69. PubMed ID: 25376540
[TBL] [Abstract][Full Text] [Related]
53. Human immunodeficiency virus type 1 Nef epitopes recognized in HLA-A2 transgenic mice in response to DNA and peptide immunization.
Sandberg JK; Leandersson AC; Devito C; Kohleisen B; Erfle V; Achour A; Levi M; Schwartz S; Kärre K; Wahren B; Hinkula J
Virology; 2000 Jul; 273(1):112-9. PubMed ID: 10891413
[TBL] [Abstract][Full Text] [Related]
54. Identification of a new HLA-A*0201-restricted CD8+ T cell epitope from hepatocellular carcinoma-associated antigen HCA587.
Li B; Wang Y; Chen J; Wu H; Chen W
Clin Exp Immunol; 2005 May; 140(2):310-9. PubMed ID: 15807856
[TBL] [Abstract][Full Text] [Related]
55. Identification of potential HLA-A *0201 restricted CTL epitopes derived from the epithelial cell adhesion molecule (Ep-CAM) and the carcinoembryonic antigen (CEA).
Ras E; van der Burg SH; Zegveld ST; Brandt RM; Kuppen PJ; Offringa R; Warnarr SO; van de Velde CJ; Melief CJ
Hum Immunol; 1997 Mar; 53(1):81-9. PubMed ID: 9127151
[TBL] [Abstract][Full Text] [Related]
56. Amino acid substitutions at position 97 in HLA-A2 segregate cytolysis from cytokine release in MART-1/Melan-A peptide AAGIGILTV-specific cytotoxic T lymphocytes.
Maeurer MJ; Chan HW; Karbach J; Salter RD; Knuth A; Lotze MT; Storkus WJ
Eur J Immunol; 1996 Nov; 26(11):2613-23. PubMed ID: 8921947
[TBL] [Abstract][Full Text] [Related]
57. Prediction of HLA class I-restricted T-cell epitopes of islet autoantigen combined with binding and dissociation assays.
Wu X; Xu X; Gu R; Wang Z; Chen H; Xu K; Zhang M; Hutton J; Yang T
Autoimmunity; 2012 Mar; 45(2):176-85. PubMed ID: 22260783
[TBL] [Abstract][Full Text] [Related]
58. Identification of HLA-A*0201/-A*2402-restricted CTL epitope-peptides derived from a novel cancer/testis antigen, MCAK, and induction of a specific antitumor immune response.
Kawamoto M; Tanaka F; Mimori K; Inoue H; Kamohara Y; Mori M
Oncol Rep; 2011 Feb; 25(2):469-76. PubMed ID: 21165574
[TBL] [Abstract][Full Text] [Related]
59. A Novel T-Cell Engaging Bi-specific Antibody Targeting the Leukemia Antigen PR1/HLA-A2.
Herrmann AC; Im JS; Pareek S; Ruiz-Vasquez W; Lu S; Sergeeva A; Mehrens J; He H; Alatrash G; Sukhumalchandra P; St John L; Clise-Dwyer K; Zha D; Molldrem JJ
Front Immunol; 2018; 9():3153. PubMed ID: 30713535
[TBL] [Abstract][Full Text] [Related]
60. Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells.
Molldrem J; Dermime S; Parker K; Jiang YZ; Mavroudis D; Hensel N; Fukushima P; Barrett AJ
Blood; 1996 Oct; 88(7):2450-7. PubMed ID: 8839835
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]